Cancer

Study: PSA Tests Cut Prostate Cancer Deaths

Published MAY 15

Story

Above: A doctor consults a patient. Image credit: Unsplash

The Facts

A new Cochrane review analyzing six trials involving nearly 800,000 men found that Prostate‐specific antigen (PSA) blood testing reduces prostate cancer deaths by roughly two per 1,000 men screened, meaning approximately 500 men must be screened to prevent one death.
Cochrane Library
Medicalxpress
The Times (UK)
The updated review marks a shift from a 2013 Cochrane review that found screening did not significantly reduce prostate cancer deaths. The new analysis includes long-term data from the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, which followed participants for up to 23 years.
Pulse
STAT
Senior author Dr. Philipp Dahm of the University of Minnesota said the findings support "a conversation about PSA screening" for "the right patient — someone who is well-informed, has a good life expectancy and understands the full implications of screening."
Independent
The Telegraph
The review found that screening detected around 30% more prostate cancers overall, with roughly 36 additional cancers diagnosed per 1,000 men screened for every one to two deaths prevented. Some of those cancers may never have caused symptoms or harm.
guardian
Medicalxpress
This comes after the U.K. National Screening Committee advised against routine NHS prostate cancer screening in November, stating that it "is likely to cause more harm than good," though it recommended screening every two years for men with BRCA1 and BRCA2 mutations between ages 45 and 61.
Independent
The Telegraph

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

This review finally confirms what many already knew — PSA screening saves lives. For too long, men have been denied a simple blood test that now has gold-standard evidence behind it. With modern MRI and smarter diagnostics, the fears of overtreatment are increasingly yesterday's argument. Every man deserves the chance at early detection.

Rishi Sunak on X

Peter Attia - MD

Narrative B

The Cochrane reversal doesn't change the core problem: screening 500 men to save one life means hundreds face biopsies, anxiety, incontinence and sexual dysfunction for cancers that would never have harmed them. A blunt test driving a cascade of irreversible treatments is a system that profits from fear.